BioDelivery Sciences International - BDSI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.60
  • Forecasted Upside: 0.18%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.59
+0 (0.00%)
Get New BioDelivery Sciences International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDSI

Analyst Price Target is $5.60
▲ +0.18% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for BioDelivery Sciences International in the last 3 months. The average price target is $5.60, with a high forecast of $5.60 and a low forecast of $5.60. The average price target represents a 0.18% upside from the last price of $5.59.

This chart shows the closing price for BDSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in BioDelivery Sciences International. This rating has held steady since February 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2022Truist FinancialDowngradeBuy ➝ HoldLow
2/18/2022Cantor FitzgeraldDowngradeOverweight ➝ Hold$5.60N/A
2/15/2022Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
2/15/2022Piper SandlerDowngradeOverweight ➝ Neutral$5.00 ➝ $5.60Low
1/21/2022HC WainwrightBoost TargetNeutral$4.00 ➝ $4.50High
11/4/2021HC WainwrightDowngradeBuy ➝ Neutral$6.00 ➝ $4.50High
10/15/2021HC WainwrightReiterated RatingBuyHigh
9/23/2021UBS GroupInitiated CoverageBuy$10.00High
8/5/2021HC WainwrightBoost TargetBuy$5.50 ➝ $6.00Medium
5/6/2021Roth CapitalLower TargetBuy$7.00 ➝ $6.25High
3/11/2021HC WainwrightLower TargetBuy$7.00 ➝ $5.50Medium
8/6/2020HC WainwrightReiterated RatingBuy$7.00High
5/25/2020Piper SandlerReiterated RatingOverweight ➝ Market Perform$9.00Medium
5/25/2020Cantor FitzgeraldReiterated RatingOverweight$8.00Medium
5/25/2020Roth CapitalReiterated RatingBuy$9.25Medium
4/22/2020Northland SecuritiesInitiated CoverageOutperform$9.00High
1/9/2020Piper SandlerInitiated CoverageOverweight$9.00Medium
12/18/2019SunTrust BanksBoost TargetBuy$8.00 ➝ $9.00Medium
11/13/2019LADENBURG THALM/SH SHBoost TargetBuy$6.00 ➝ $8.00High
11/13/2019Janney Montgomery ScottReiterated RatingBuyHigh
9/17/2019William BlairReiterated RatingBuyLow
5/10/2019Cantor FitzgeraldSet TargetBuy$8.00Low
4/26/2019Cantor FitzgeraldSet TargetBuy$8.00Medium
4/16/2019Cantor FitzgeraldReiterated RatingBuy$8.00Low
4/5/2019Cantor FitzgeraldSet TargetBuy$8.00Low
3/22/2019Cantor FitzgeraldSet TargetBuy$8.00Medium
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$7.00High
3/15/2019HC WainwrightReiterated RatingBuy$6.00High
3/14/2019Cantor FitzgeraldReiterated RatingBuy$8.00High
3/8/2019Cantor FitzgeraldReiterated RatingBuyMedium
2/15/2019Cantor FitzgeraldSet TargetBuy$5.00High
2/8/2019Cantor FitzgeraldReiterated RatingBuy$5.00Low
1/31/2019Janney Montgomery ScottReiterated RatingBuy ➝ Buy$5.00Low
1/25/2019Cantor FitzgeraldSet TargetBuy$5.00Medium
12/27/2018Cantor FitzgeraldSet TargetBuy$5.00High
12/13/2018Cantor FitzgeraldReiterated RatingBuy$5.00High
11/2/2018HC WainwrightReiterated RatingBuy$5.00Medium
11/2/2018Janney Montgomery ScottBoost TargetBuy$5.00Medium
10/26/2018Cantor FitzgeraldSet TargetBuy$5.00Low
10/8/2018HC WainwrightSet TargetBuy$5.00High
10/7/2018Cantor FitzgeraldSet TargetBuy$5.00High
8/10/2018HC WainwrightReiterated RatingBuy$4.00Low
8/9/2018Cantor FitzgeraldReiterated RatingBuy$4.50Medium
7/6/2018HC WainwrightReiterated RatingBuy$4.00Medium
6/5/2018Cantor FitzgeraldSet TargetBuy$5.00High
5/23/2018HC WainwrightLower TargetBuy ➝ Buy$4.00 ➝ $3.50Low
5/13/2018HC WainwrightSet TargetBuy$4.00High
5/11/2018Roth CapitalSet TargetBuy$5.00 ➝ $4.00Medium
5/7/2018HC WainwrightReiterated RatingBuy$4.00High
5/7/2018Cantor FitzgeraldSet TargetBuy$5.00High
4/13/2018HC WainwrightSet TargetBuy$4.00Low
3/19/2018HC WainwrightSet TargetBuy$4.00High
3/15/2018Cantor FitzgeraldReiterated RatingBuy$5.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
BioDelivery Sciences International logo
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
Read More

Today's Range

Now: $5.59
Low: $5.59
High: $5.60

50 Day Range

MA: $5.58
Low: $5.54
High: $5.60

52 Week Range

Now: $5.59
Low: $2.50
High: $5.62

Volume

2,090,567 shs

Average Volume

3,340,554 shs

Market Capitalization

$577.05 million

P/E Ratio

6.74

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of BioDelivery Sciences International?

The following equities research analysts have issued research reports on BioDelivery Sciences International in the last year: Cantor Fitzgerald, Northland Securities, Piper Sandler, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for BDSI.

What is the current price target for BioDelivery Sciences International?

2 Wall Street analysts have set twelve-month price targets for BioDelivery Sciences International in the last year. Their average twelve-month price target is $5.60, suggesting a possible upside of 0.2%. Cantor Fitzgerald has the highest price target set, predicting BDSI will reach $5.60 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $5.60 for BioDelivery Sciences International in the next year.
View the latest price targets for BDSI.

What is the current consensus analyst rating for BioDelivery Sciences International?

BioDelivery Sciences International currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BDSI, but not buy more shares or sell existing shares.
View the latest ratings for BDSI.

What other companies compete with BioDelivery Sciences International?

How do I contact BioDelivery Sciences International's investor relations team?

BioDelivery Sciences International's physical mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company's listed phone number is (919) 582-9050 and its investor relations email address is [email protected] The official website for BioDelivery Sciences International is www.bdsi.com. Learn More about contacing BioDelivery Sciences International investor relations.